Safety of LAMA/LABA combination therapy in the COPD patients

Safety of LAMA/LABA combination therapy in the COPD patients - Safety of LAMA/LABA combination therapy in the COPD patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034641

Enrollment

Registered

2018-10-25

Start date

2018-10-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Tiotropium Bromide Hydrate, Olodaterol Hydrochloride Glycopyrronium Bromide, Indacaterol Maleate Umeclidinium Bromide, Vilanterol Trifenatate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: COPD patients

Exclusion criteria

Exclusion criteria: patients on HOT patients who used ICS inhaler and/or Muscarinic antagonist during oral steroid glaucoma

Design outcomes

Primary

Measure	Time frame
the differences of the intraocular pressure and the residual urine volume pre and post treatment	—

Countries

Japan

Contacts

Public ContactNaoki Miyao

Nippon Koukan Hospiatal internal medicine

naoki-miyao@koukankai.or.jp0443335591

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026